neurocrine.com (NBIX) Price-to-Projected Revenue Ratio

Corporate emblem and logo of Neurocrine Corp (NBIX)

The fundamental success of Neurocrine Biosciences (NBIX) relies on Ingrezza's dominance in dyskinesia therapy and FDA approval of new molecules. The forward price-to-sales ratio clearly demonstrates market expectations, with the indicator standing at 3.30. A steady influx of patients is ensured by the absence of analogues, while innovation is accelerated through strategic partnerships with global pharma behemoths and joint research.

Neurocrine - NBIX Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/18/2026)

Neurocrine Biosciences (NBIX) - metric breakdowns and financial figures

- current price and projected stock value:
Comprehensive company analysis:NBIX (neurocrine.com)
Product sample of Neurocrine Corp

The forward P/S ratio determines the market value of a company relative to its expected sales volume, making it possible to identify whether an asset is overvalued or hiddenly undervalued. Investors utilize this multiple to distinguish fundamentally strong companies from "value traps," where a low ratio signals business degradation. When analyzing the forward price-to-sales chart for Neurocrine Biosciences (NBIX), it is critical to consider the revenue dependence on the patent protection of a narrow drug portfolio and the risks associated with clinical trials.

Competitor analysis

Forward P/S Multiple BIIB (Biogen Idec)|Regencell Bioscience - Price-to-Projected Revenue Ratio|Axsome Therapeutics - Forward P/S Multiple|Forward Price to Sales ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Forward P/S Multiple|CPRX: Forward Price to Sales|Forward P/S Multiple DNLI|Market Cap to Expected Sales Ratio Harmony Biosciences|Biohaven Ltd - Forward Price-to-Revenue Multiple|Forward P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Praxis Corp PRAX|AVXL: Forward P/S Multiple|CBLL (ceribell.com) - Price-to-Projected Revenue Ratio|PRTA (Prothena Corporation) - Forward P/S Multiple|Forward Price-to-Revenue Multiple alector.com (ALEC)|Price-to-Projected Revenue Ratio Annexon, Inc. (ANNX)|OMER - Market Cap to Future Revenue Ratio|Forward P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Market Cap to Future Revenue Ratio|Voyager Therapeutics Inc - Forward P/S Multiple|Neumora (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple cogrx.com (CGTX)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Market Cap to Expected Sales Ratio Cassava Sciences|Forward P/S Multiple ASRT (Assertio Holdings)|COYA - Forward Price-to-Revenue Multiple|vistagen.com - Forward P/S Multiple|OVID: Price-to-Projected Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Projected Revenue Ratio|CervoMed Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple